Navigation Links
Need for federal protection against genetic discrimination
Date:3/24/2008

Washington A policy monograph highlighting the need for federal protections against genetic discrimination in employment and insurance practices was released today by the American College of Physicians (ACP). The six policy positions ACP believes should be included in the federal protections are the focus of the policy paper. http://www.acponline.org/advocacy/where_we_stand/policy/index.html.

While theyre not quite there, Congress does continue to move closer to passing federal legislation that protects the use of genetic information in employment and insurance coverage decisions, noted David C. Dale, MD, FACP president of the 125,000 member ACP. This monograph is important for the ongoing discussion.

ACPs first two positions consider insurance providers:

Position 1: Insurance providers should be prohibited from using an individuals genetic information to deny or limit health coverage or establish eligibility, enrollment, or premium contribution requirements.

Position 2: Insurance providers should be prohibited from establishing differential premiums based on an individuals genetic information or request for genetic screening.

ACPs policy positions result from a March 2007 survey conducted by the John Hopkins Genetics and Public Policy Center. It found that 86 percent of patients trust their physicians and 66 percent of patients trust genetic researchers with access to their genetic information. However, most people do not trust health insurers and employers not to misuse their genetic information through disclosure or discriminatory practices- should they have access to it.

The Colleges third position says:

Position 3: Employers should be prohibited from using an individuals genetic information in employment decisions, such as hiring, promoting, or terminating an employee or establishing the terms, conditions, and benefits or employment.

The ACP research looked at a report done by the National Partnership for Women and Families on behalf of the Coalition for Genetic Fairness that documents how fears of genetic discrimination negatively impact patient health care and financial well-being, public health, and scientific advancements. Examples include shielding genetic information from health care providers, refusing genetic testing, or undergoing testing using an alias.

Two more ACP positions which consider insurers and employers are:

Position 4: Insurers and employers should be prohibited from requiring individuals and families to undergo genetic testing

Position 5: Insurers and employers should be prohibited from collecting and/or disclosing an individual or familys genetic information. Written and informed consent should be required for each disclosure of genetic information and should include to whom the disclosure is made.

Finally, ACP considered specific Congressional considerations:

Position 6: Congress should establish comprehensive and uniform federal protection against genetic discrimination that closes the gaps in protection due to varying state laws. Federal protection should also cover ERISA health plans.


'/>"/>

Contact: David Kinsman
dkinsman@acponline.org
202-261-4554
American College of Physicians
Source:Eurekalert

Related biology news :

1. SNM applauds NAS study showing need to restore federal nuclear medicine research funding
2. NOAA proposes federal regulations to protect black abalone
3. 2 federal public health grants awarded to Weill Cornell Medical College
4. $13 million federal grant for research into vascular disease awarded to Weill Cornell
5. HR Initiative Endorses Bill to Create an Effective, Mandatory Federal Employment Verification System
6. Poll Shows Strong Doubts About Effectiveness of Federal Employment Verification System
7. Rain forest protection works in Peru
8. Antioxidants could provide all-purpose radiation protection
9. Secure Services Corp. Achieves Milestone in United States Identity Protection with the Launch of the SSC SHAPE Card Management Solution
10. Better protection for biomedial devices could result from Rutgers-Camden research
11. A search for protection against chemotherapy cardiotoxicity
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... BANGALORE, India , April 28, 2016 ... subsidiary of Infosys (NYSE: INFY ), and Samsung ... global partnership that will provide end customers with a ... and payment services.      (Logo: http://photos.prnewswire.com/prnh/20130122/589162 ... for financial services, but it also plays a fundamental part ...
(Date:4/19/2016)... , UAE, April 20, 2016 ... implemented as a compact web-based "all-in-one" system solution for ... biometric fingerprint reader or the door interface with integration ... modern access control systems. The minimal dimensions of the ... readers into the building installations offer considerable freedom of ...
(Date:4/13/2016)... physicians supporting Medicaid patients in Central Florida ... telehealth thanks to a new partnership with higi.   ... can routinely track key health measurements, such as blood ... they opt in, share them with IMPOWER clinicians through ... location at no cost. By leveraging this data, IMPOWER ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... ... June 27, 2016 , ... Parallel 6 , ... announced today the Clinical Reach Virtual Patient Encounter CONSULT module which enables ... the physician and clinical trial team. , Using the CONSULT module, patients and physicians ...
(Date:6/27/2016)... June 27, 2016   Ginkgo Bioworks , a ... engineering, was today awarded as one of the ... the world,s most innovative companies. Ginkgo Bioworks is ... the real world in the nutrition, health and ... directly with customers including Fortune 500 companies to ...
(Date:6/24/2016)... Raleigh, NC (PRWEB) , ... June 24, 2016 , ... ... find the most commonly-identified miRNAs in people with peritoneal or pleural mesothelioma. Their findings ... here to read it now. , Diagnostic biomarkers are signposts in the blood, ...
(Date:6/23/2016)... - FACIT has announced the creation of a ... Propellon Therapeutics Inc. ("Propellon" or "the Company"), to ... of first-in-class WDR5 inhibitors for the treatment of ... an exciting class of therapies, possessing the potential ... patients. Substantial advances have been achieved with the ...
Breaking Biology Technology: